Non-insulin-dependent Diabetes Mellitus Induced by Immune Checkpoint Inhibitor Therapy in an Insulinoma-associated Antigen-2 Autoantibody-positive Patient with Advanced Gastric Cancer-Reference-Cited by-同舟云学术

Non-insulin-dependent Diabetes Mellitus Induced by Immune Checkpoint Inhibitor Therapy in an Insulinoma-associated Antigen-2 Autoantibody-positive Patient with Advanced Gastric Cancer

Published:2020-02-15 Issue:4 Volume:59 Page:551-556
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Ohara Nobumasa¹,Kobayashi Michi¹²,Ikeda Yohei³,Hoshi Takahiro⁴,Morita Shinichi⁴,Kanefuji Tsutomu⁴,Yagi Kazuyoshi⁴,Suda Takeshi⁴,Takada Toshinori⁵,Hasegawa Go⁶,Sato Yo⁷,Hirano Kenichiro⁷,Kosugi Shin-ichi⁷

Affiliation:

1. Department of Endocrinology and Metabolism, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Japan

2. Department of Diabetes, Endocrinology and Metabolism, Center Hospital of the National Center for Global Health and Medicine, Japan

3. Department of Radiology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Japan

4. Department of Gastroenterology and Hepatology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Japan

5. Department of Respiratory Medicine, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Japan

6. Department of Pathology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Japan

7. Department of Digestive and General Surgery, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/59/4/59_3208-19/_pdf

Reference25 articles.

1. 1. Pennock GK, Chow LQ. The evolving role of immune checkpoint inhibitors in cancer treatment. Oncologist 20: 812-822, 2015.

2. 2. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54: 139-148, 2016.

3. 3. Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4: 173-182, 2018.

4. 4. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 37 (Suppl 1): S81-S90, 2014.

5. 5. Winter WE, Schatz DA. Autoimmune markers in diabetes. Clin Chem 57: 168-175, 2011.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of preoperative type 2 diabetes mellitus on the outcomes of patients with gastric cancer following gastrectomy: Analysis of 834 patients using propensity score matching;Biomedical Reports;2023-10-19

2. Risk Factors and Characteristics of Checkpoint Inhibitor–Associated Autoimmune Diabetes Mellitus (CIADM): A Systematic Review and Delineation From Type 1 Diabetes;Diabetes Care;2023-05-23

3. Immune checkpoint inhibitor-induced diabetes mellitus with nivolumab;BMJ Case Reports;2023-04

5. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus;Translational Oncology;2022-10